FORWARD study

  • Research type

    Research Study

  • Full title

    An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome

  • IRAS ID

    1012577

  • Contact name

    Jamie Dananberg

  • Contact email

    jdananberg@annexonbio.com

  • Sponsor organisation

    Annexon, Inc.

  • Clinicaltrials.gov Identifier

    NCT07020819

  • Research summary

    ​​This research study is looking at a potential new treatment for Guillain-Barré Syndrome (GBS), a rare condition in which the body’s immune system attacks the nerves. GBS can cause muscle weakness, numbness, and even paralysis. It usually develops suddenly and can be life-threatening, but early treatment may improve recovery.
    ​
    ​The study will test a medicine called ANX005, which is designed to block part of the immune system (called “complement”) that is thought to play a role in GBS. ANX005 will be given as a one-time intravenous (IV) infusion over 18 hours. The study aims to understand how the medicine moves through and affects the body (pharmacokinetics and pharmacodynamics), as well as its safety and early signs of effectiveness.
    ​
    ​About 30 participants with GBS will take part. All will receive a single dose of ANX005 in hospital, alongside standard supportive care. Other common GBS treatments, such as intravenous immunoglobulin (IVIg) or plasma exchange (a process that filters the blood), will not be used at the same time. However, these treatments may be given later if doctors feel they are needed.

    ​Participants will stay in hospital for at least eight days and will have follow-up appointments up to Week 26, either in person or remotely. The results will also be compared to information from a separate group of people with GBS who were treated with IVIg in a past study.

    ​This is an international study taking place at several hospital sites. It is sponsored by Annexon, Inc., the company developing ANX005. The findings may help doctors understand whether ANX005 could be a useful new treatment for people with GBS.​

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0239

  • Date of REC Opinion

    15 Dec 2025

  • REC opinion

    Further Information Favourable Opinion